BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
Harvard Business School
McKesson
Medtronic
UBS
Dow
Farmers Insurance
Cantor Fitzgerald
Citi

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: RE32393

« Back to Dashboard

Summary for Patent: RE32393
Title: Composition for enhancing the administration of pharmacologically active agents
Abstract:According to the invention, the parenteral administration of water-insoluble pharmacologically active agents is enhanced wherein the agents are administered in the lipoid phase of a carrier emulsion comprising a microemulsion of a finely dispersed lipoid in an aqueous phase. The lipoid preferably has a mean particle size below 1 micron. This makes it possible to administer water-insoluble agents in high concentrations, and thus a lower dose, whereby a rapid onset of the pharmacological effect is accompanied by a markedly reduced incidence of injury to body tissues.
Inventor(s): Wretlind; Karl A. J. (Stockholm, SE), Ljungberg; Stellan (Lidingo, SE), Hakansson; Ivan (Stockholm, SE), Ajaxon; Bengt M. (Upsala, SE)
Assignee: KabiVitrum AB (Stockholm, SE)
Application Number:06/605,760
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent RE32393

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE32393

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden12159/67Sep 1, 1967

International Patents Family Members for US Patent RE32393

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 1792410 ➤ Subscribe
Denmark 129272 ➤ Subscribe
France 1593013 ➤ Subscribe
France 8152 ➤ Subscribe
United Kingdom 1229967 ➤ Subscribe
Netherlands 6812429 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Covington
Mallinckrodt
Cerilliant
Daiichi Sankyo
US Army
Chubb
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot